1
Home
Companies

MeiraGTx

#6882

Rank

$525.59M

Marketcap

US United States

Country

MeiraGTx
Leadership team

Dr. Alexandria Forbes (CEO, Pres & Director)

Mr. Richard Brian Giroux B.A. (COO & CFO)

Dr. Robert K. Zeldin M.D. (Chief Medical Officer)

Products/ Services
Biotechnology, Health Care, Therapeutics
Number of Employees
100 - 500
Headquarters
New York, New York, United States
Established
2015
Company Registration
SEC CIK number: 0001735438
Revenue
20M - 100M
Traded as
MGTX
Social Media
URL
https://www.meiragtx.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. MeiraGTx Holdings plc was incorporated in 2015 and is based in New York, New York.
History

MeiraGTx was founded in September 2015. The company quickly grew from a small three-person team to a fully integrated global gene therapy company with over 300 employees globally. The company has raised over $300 million in series A/B/C financing and has built an outstanding IP portfolio with 500+ issued and pending patents worldwide.

Mission
Our mission is to deliver transformative gene therapy treatments to address the genetic cause of diseases, offering new hope to patients
Vision
Transforming Care through Molecular Medicine
Key Team

Mr. Robert J. Wollin J.D. (Gen. Counsel & Sec.)

Dr. Stuart Naylor Ph.D. (Chief Devel. Officer)

Dr. Michel Michaelides M.D. (Head of Clinical Ophthalmology)

Ms. Christine Elise Sheehy (Sr. VP of Global Integration)

Dr. Alastair Leighton Ph.D. (Sr. VP of Manufacturing & Supply Chain)

Mr. Joel P. Brooks (Sr. VP of Fin.)

Mr. Tim Randall (Sr. VP of Risk & Internal Controls)

Recognition and Awards
MeiraGTx has seen remarkable success in its short history, winning awards such as the prestigious ‘European Investment Award’ and ‘R&D 100 Award’
References

https://in.investing.com/equities/meiragtx-holdings

https://finance.yahoo.com/quote/MGTX/profile?p=MGTX

https://www.crunchbase.com/organization/meiragtx

https://companiesmarketcap.com/

https://www.meiragtx.com

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

MeiraGTx
Leadership team

Dr. Alexandria Forbes (CEO, Pres & Director)

Mr. Richard Brian Giroux B.A. (COO & CFO)

Dr. Robert K. Zeldin M.D. (Chief Medical Officer)

Products/ Services
Biotechnology, Health Care, Therapeutics
Number of Employees
100 - 500
Headquarters
New York, New York, United States
Established
2015
Company Registration
SEC CIK number: 0001735438
Revenue
20M - 100M
Traded as
MGTX
Social Media
URL
https://www.meiragtx.com